Related references
Note: Only part of the references are listed.Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients
Sergio Siragusa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Conventional cytogenetics in myelofibrosis: literature review and discussion
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients
T. L. Lasho et al.
LEUKEMIA (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis:: cytogenetic and JAK2V617F molecular remissions
A. Tefferi et al.
LEUKEMIA (2007)
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2007)
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
Daniella M. B. Kerbauy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
Share Paper
